NEW YORK, NY / CRWEPRESSRELEASE / September 8, 2015 /Market Exclusive announces that JMP Securities has initiated coverage of Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) with a Market Outperform rating and a 12-month price target of $6 per share.
Corbus is a biopharmaceutical company focused on developing Resunab as a novel therapy for the treatment of rare diseases characterized by excessive and chronic inflammation. The company is initiating a series of Phase 2 studies in several rare diseases, including cystic fibrosis, systemic scleroderma and dermatomyositis, to test Resunab’s potential in resolving inflammation. Commenting on the investment highlights of Corbus Pharmaceuticals, JMP Securities analysts Liisa Bayko and Masha Chapman wrote, “While Corbus remains under the radar screen for many investors, we believe proof-of-concept data from these studies in the late 2016 to early 2017 timeframe that show a benefit in any of these indications will increase the company’s visibility and drive share appreciation.”
About Market Exclusive
Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.
The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
SOURCE: Market Exclusive